Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
The Top 25 Healthcare Technology Leaders of Massachusetts for 2023 | The Healthcare Technology Report.
MS Therapies are Focus of Abarca-Biogen Value-based Reimbursement Contract
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
Abarca Announces Innovative Value-Based Contract with Biogen
What Biogen CFO's Departure Means for Company's M&A Strategy | BioSpace
Jean-Paul Kress, M.D. | Morphosys de
David Khougazian appointed president of Sanofi Pasteur MSD - PMLiVE
Jean-Paul Kress Net Worth (2023) | wallmine
Jean-Paul Kress, Morphosys AG: Profile and Biography - Bloomberg Markets
Chutes & Ladders—Biogen executive Kress takes over the reins of Syntimmune | Fierce Biotech
Jean-Paul Kress email address & phone number | Morphosys Chairman of the Board of Management, Chief Executive Officer contact information - RocketReach
Exhibit 99.1
Sanofi Genzyme exec jumps ship to join Biogen
Jean-Paul Kress Appointed EVP and President, International and Head of Global Therapeutic Operations | Business Wire
New CEO at Morphosys - European Biotechnology
MorphoSys acquires Constellation Pharma for $1.7B - Boston Business Journal
Kress becomes new CEO of MorphoSys - BioM
Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
Morphosys: Missmanagement bei Deutschlands einstigem Biotechstar - manager magazin
Jean-Paul Kress M.D. — Executive VP, President of International, Head of Global Therapeutic Operations at Biogen | Comparably
